LONDRES - Mardi 11 Décembre 2012 [ME NewsWire]

(BUSINESS WIRE)--Le prestigieux Centre international d’études parlementaires (International Centre for Parliamentary Studies, ICPS) a délivré le 6e Certificat professionnel en processus électoraux, dans le cadre du programme de formation spécialisée offert par cette institution pour les agents électoraux internationaux.

Du 26 au 30 novembre, un panel d’experts en élections a donné des conférences sur des sujets liés aux pratiques et procédures électorales actuelles, en vue d’offrir un panorama détaillé des thèmes actuels et formations spéciales pour les professionnels travaillant dans ce domaine.

Smartmatic, fournisseur leader de technologie qui a mené à bien les votes électroniques sur la plus grande échelle au monde grâce à des scanneurs optiques (Philippines) et des machines à v ... Read more »

Shell, RockPort Capital, Nth Power and Chrysalix Energy Venture Capital invest in GlassPoint to drive large-scale solar EOR deployment

FREMONT, Calif. & MUSCAT, Oman - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)-- GlassPoint SolarInc., a leader in solar enhanced oil recovery (EOR), today announced it has closed a US$26 million Series B financing round. The round included participation from a new strategic investor, Royal Dutch Shellplc group, one of the world’s largest oil companies, as well as leading energy investors RockPort Capital, Nth Powerand Chrysalix Energy Venture Capital, an existing investor. The funding is a key next step to future large-scale deployment of GlassPoint’s solar steam technology in EOR projects around the world.

GlassPoint’s unique design encloses parabolic troughs inside a glasshouse structure, which protects the system from high winds and seals the solar collectors from dust, dirt, sand and humidity. The protected env ... Read more »

Dubai, United Arab Emirates - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)-- The Internet Society releases the following statement from President and CEO Lynn St. Amour.

"The World Conference on International Telecommunications (WCIT) is an important event that the Internet Society hopes will contribute to greater connectivity and growth in international telecommunications for the public. Over the last week and throughout the weekend, ITU Member States were engaged in hard and difficult negotiations to move the work of the conference forward positively.

As the conference moves back into plenary session today, we are seeing the first results of delegates' efforts in the form of proposals to modify existing treaty text and insert new text into the International Telecommunication Regulations (ITRs). In reviewing these texts, and noting that bracketed text remains unresolved, it is increasingly clear that the fundamental question facing delegates is whethe ... Read more »

INGELHEIM, Germany - Tuesday, December 11th 2012 [ME NewsWire]

    Phase II study demonstrated higher rates of objective response and an improvement in event free survival (EFS) in patients with acute myeloid leukaemia (AML) receiving volasertib* in combination with low-dose cytarabine (LDAC) versus LDAC alone
    Phase III study of volasertib* in AML is planned to be initiated in early 2013

(BUSINESS WIRE)-- For NON-US media only

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company’s investigational haematology/oncology compound volasertib* in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA. In this study, higher rates of objective response (primary endpoint) and an improvement in event free survival (secon ... Read more »

Leading Zimbabwe bank upgrades to latest version of TSYS solution

COLUMBUS, Ga. & DUBAI, United Arab Emirates - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)-- TSYS (NYSE: TSS) announced today that Zimbabwe’s NMB Bank Limited (NMB) has signed an agreement to migrate its Visa credit card portfolio to PRIME 4, the latest version of the TSYS licensed card and merchant management solution.

NMB has been a TSYS client since 2001 when it first licensed a card management solution to begin issuing Visa credit cards in Zimbabwe. NMB will use PRIME 4 to manage its cards issuing and cash acquiring as it seeks to expand its range of card services for consumers and businesses.

"It is important that NMB’s business evolves along with our clients’ needs and market changes. As such, TSYS remains our trusted systems provider because it continues to offer us the security of a stable, compliant platform coupled with the flexibility for future growth,” said Benef ... Read more »

LONDON - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)--The prestigious International Centre for Parliamentary Studies (ICPS) recently delivered the 6th Professional Certificate in Electoral Processes, as part of the specialised training programme, offered by the institution, for international electoral officials.

From November 26 to 30, a panel of electoral experts lectured on subjects related to current electoral practices and procedures, to offer an exhaustive perspective in current topics and special training for professionals working in the field.

Smartmatic, a leading technology supplier that has carried out the largest-scale e-voting events in the world with optical scanners (the Philippines) and with voting machines featuring printed vouchers (Venezuela), participated in the programme hosting two sessions by Heider Garcia, Director of Electoral Solutions. The first session, titled "Election Management: from hiring to delivery of results, how to ... Read more »

ATLANTA - Tuesday, December 11th 2012 [ME NewsWire]

(BUSINESS WIRE)-- Millennium: The Takeda Oncology Companywith its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced the presentation of data from a phase 1 study investigating once a week MLN9708 in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The primary objectives of this open-label, dose-escalation, phase 1 study were to determine the safety, tolerability, and maximum tolerated dose (MTD) of MLN9708 in patients with relapsed or refractory AL, and to determine the dose for future development. Once the MTD was reached, two expansion cohorts were enrolled, one with proteasome inhibitor-naïve patients (n=5) and one with proteasome inhibitor-exposed patients (n=12). The data were presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition held December 8-11, 2012 in Atlanta, GA.

"Preliminary evidence of hematologic responses and early ... Read more »

ME Newswire / Business Wire

VILLEJUIF, France - Monday, December 10th 2012

Worldwide Innovative Network (WIN) in personalized cancer medicine consortium today proudly announced that Pfizer, Inc(NYSE:PFE) is the first pharmaceutical company to become a member of the consortium. Founded on the recognition that greater success can be achieved through collaboration than any organization can achieve alone, the WIN Consortium is a global network of leading academic, industry, and patient advocacy organizations working to make personalized cancer care a reality for patients worldwide.

Pfizer’s strong corporate commitment to the development of drugs using a precision medicine approach, coupled with the company’s deep breadth of experience in the development of oncology therapeutics, strategically align the company’s goals and capabilities with the mission of the WIN Consortium. As the newest member of the consortium, Pfizer will play an integral role in shaping the future ... Read more »

INGELHEIM, Germany - Monday, December 10th 2012 [ME NewsWire]

    In RE-LY®, patients had better survival prognosis and spent less time in intensive care following a major bleed with Pradaxa® (dabigatran etexilate) than with warfarin
    Data provide further support for the favourable safety profile of Pradaxa®
    Presentation at American Society of Hematology (ASH) 2012 highlighted as ‘Best of ASH’

(BUSINESS WIRE)-- For Non-US, Non-UK & Non-Canadian Media Only

Results from a new post-hoc analysis of the landmark RE-LY®i trial show that in patients experiencing a major bleeding event, treatment with Pradaxa® (dabigatran etexilate) was associated with lower mortality and a shorter length of stay in intensive care compared to warfarin. In a pooled post-hoc analysis of five Phase III trials with Pradaxa®, the data show a clear trend towards a better prognosis after a major bleed with Prada ... Read more »

ATLANTA - Sunday, December 9th 2012 [ME NewsWire]

MLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone

(BUSINESS WIRE)-- Millennium: The Takeda Oncology Companywith its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today reported data from a phase 1 / 2 study of once a week investigational MLN9708 in combination with standard dose lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma (MM). The previously reported phase 1 portion of the study was a dose escalation study to determine the safety, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of MLN9708 in combination with lenalidomide and dexamethasone. The primary objectives of the ongoing phase 2 portion of the study are to determine the combined complete and very good partial response rates (≥VGPR), safety and tolerability. Secondary objectives include overall resp ... Read more »